The primary role of our Board is to protect and enhance medium to long term shareholder value through the provision of strategic direction and corporate governance of Vitura Health Limited. Bringing a wealth of knowledge and experience, our Board carries a diverse background of expertise.
Our Board
Robert Iervasi
Independent Chair and Non- Executive Director
Robert Iervasi was appointed Chair of Vitura on 13 February 2024. He is an astute leader in the consumer products industry, leading Asahi Beverages as Group Chief Executive Officer and Board Director from 2019 - 2023, and as Group Chief Operating Officer, Group CFO & General Counsel for the preceding eight years. Before joining Asahi, he was the Legal, Tax, Treasury & Risk Director at Cadbury Schweppes and a principal legal advisor at Coles Group Limited. His legal experience extends to private practice, covering litigation, tax, general corporate and mergers & acquisition.
He has a track record of delivering revenue and cost synergies, executing strategic opportunities, and driving profitability and growth across multiple categories, brands, and channels.
Robert holds an LLB (Hons) and BCom (Hons) from Monash University, completed the Senior Executive Program at London Business School and further study focused on exploiting disruption in a digital world. A Graduate of the Australian Institute of Company Directors, he was selected as a Young Executive 2012 by the Australian Financial Review.
Beyond Vitura, he sits on the Board of SPC Global as Non-Executive Director, Luv-A-Duck as Chairman and Charters Papers as Executive Chairman.
Robert Iervasi was appointed Chair of Vitura on 13 February 2024. He is an astute leader in the consumer products industry, leading Asahi Beverages as Group Chief Executive Officer and Board Director from 2019 - 2023, and as Group Chief Operating Officer, Group CFO & General Counsel for the preceding eight years. Before joining Asahi, he was the Legal, Tax, Treasury & Risk Director at Cadbury Schweppes and a principal legal advisor at Coles Group Limited. His legal experience extends to private practice, covering litigation, tax, general corporate and mergers & acquisition.
He has a track record of delivering revenue and cost synergies, executing strategic opportunities, and driving profitability and growth across multiple categories, brands, and channels.
Robert holds an LLB (Hons) and BCom (Hons) from Monash University, completed the Senior Executive Program at London Business School and further study focused on exploiting disruption in a digital world. A Graduate of the Australian Institute of Company Directors, he was selected as a Young Executive 2012 by the Australian Financial Review.
Beyond Vitura, he sits on the Board of SPC Global as Non-Executive Director, Luv-A-Duck as Chairman and Charters Papers as Executive Chairman.
Daniel Birch
Independent Non- Executive Director
Daniel Birch is a commercially astute and highly experienced lawyer with nearly two decades of expertise in delivering strategic legal counsel across diverse industries, providing informed, solution-driven advice. His extensive experience includes advising companies in the Medicinal Cannabis and scheduled drugs sectors, notably serving as the primary legal advisor to CDA Health and its subsidiaries prior to its merger with Cronos. Daniel's deep understanding of regulated industries, compliance frameworks, and distribution operations makes him a valuable asset in navigating complex legal landscapes. Daniel is Partner and Head of Commercial and Corporate at Stone Group Lawyers. He holds a Bachelor of Laws, a Graduate Diploma in Law Practice, and a Bachelor of International Business from Griffith University. His comprehensive knowledge and strategic insights position him as a trusted advisor in the legal and corporate arenas.
Daniel Birch is a commercially astute and highly experienced lawyer with nearly two decades of expertise in delivering strategic legal counsel across diverse industries, providing informed, solution-driven advice. His extensive experience includes advising companies in the Medicinal Cannabis and scheduled drugs sectors, notably serving as the primary legal advisor to CDA Health and its subsidiaries prior to its merger with Cronos. Daniel's deep understanding of regulated industries, compliance frameworks, and distribution operations makes him a valuable asset in navigating complex legal landscapes. Daniel is Partner and Head of Commercial and Corporate at Stone Group Lawyers. He holds a Bachelor of Laws, a Graduate Diploma in Law Practice, and a Bachelor of International Business from Griffith University. His comprehensive knowledge and strategic insights position him as a trusted advisor in the legal and corporate arenas.
Gerard Fogarty
Independent Non- Executive Director
Gerard Fogarty was appointed Non-Executive Director of Vitura on 27 November 2024. Gerard is an experienced non-executive director and CEO. His board and executive roles have encompassed a variety of sectors, including national security, industrial relations regulation, work health and safety regulation, compensation and rehabilitation regulation, medical research, human performance research and health insurance. His background spans diverse entities, including statutory authorities, joint ventures, industry bodies, not-for-profits and advisory boards. He was most recently a highly successful CEO of a private health insurer, leading it to repeated national customer satisfaction and employer of choice awards.
Gerard Fogarty was appointed Non-Executive Director of Vitura on 27 November 2024. Gerard is an experienced non-executive director and CEO. His board and executive roles have encompassed a variety of sectors, including national security, industrial relations regulation, work health and safety regulation, compensation and rehabilitation regulation, medical research, human performance research and health insurance. His background spans diverse entities, including statutory authorities, joint ventures, industry bodies, not-for-profits and advisory boards. He was most recently a highly successful CEO of a private health insurer, leading it to repeated national customer satisfaction and employer of choice awards.
Rebecca Wilson
Independent Non- Executive Director
Rebecca Wilson is an experienced company director with private, ASX-listed and not-for-profit organisations. She is currently the Non-Executive Chair of global healthcare technology company, Alcidion Limited (ASX: ALC), and Ai-enabled technology platform LBT Innovations (ASX: LBT), and a Non-Executive Director of ASX listed enterprise technology company Hansen Technologies (ASX: HSN), and not-for-profit Tomisich Foundation. In an executive career spanning 25 years, she held global leadership roles in marketing communication, brand positioning, investor relations, capital management, and corporate affairs. She has deep expertise in ESG, complex stakeholder communication, brand awareness, issues, crisis and risk management, transactions, and investor relations. Rebecca is industry agnostic, having worked with multinational and growth companies in technology, healthcare, retail and FMCG, and professional services. She has deep experience leading companies in important commercial activation phases working with CEOs as both an advisor and Non-Executive Director to develop and execute effective business strategy that supports accelerated and sustained growth. She’s worked as a NED since 2017, including Committee representation on Remuneration and Nominations (including as Chair), M&A, ESG, and Audit and Risk. In addition to her non-executive boards, she continues to provide consulting services to boards and executive management teams.
BA (Deakin), Grad Cert Applied Finance & Investment (Kaplan), GAICD
Rebecca Wilson is an experienced company director with private, ASX-listed and not-for-profit organisations. She is currently the Non-Executive Chair of global healthcare technology company, Alcidion Limited (ASX: ALC), and Ai-enabled technology platform LBT Innovations (ASX: LBT), and a Non-Executive Director of ASX listed enterprise technology company Hansen Technologies (ASX: HSN), and not-for-profit Tomisich Foundation. In an executive career spanning 25 years, she held global leadership roles in marketing communication, brand positioning, investor relations, capital management, and corporate affairs. She has deep expertise in ESG, complex stakeholder communication, brand awareness, issues, crisis and risk management, transactions, and investor relations. Rebecca is industry agnostic, having worked with multinational and growth companies in technology, healthcare, retail and FMCG, and professional services. She has deep experience leading companies in important commercial activation phases working with CEOs as both an advisor and Non-Executive Director to develop and execute effective business strategy that supports accelerated and sustained growth. She’s worked as a NED since 2017, including Committee representation on Remuneration and Nominations (including as Chair), M&A, ESG, and Audit and Risk. In addition to her non-executive boards, she continues to provide consulting services to boards and executive management teams.
BA (Deakin), Grad Cert Applied Finance & Investment (Kaplan), GAICD
Shane Tanner
Independent Non- Executive Director
Shane Tanner was appointed Non-Executive Director of Vitura on 27 November 2024, having previously served as the Company’s Independent Chair from 9 October 2018 to 11 April 2022. Shane is an experienced and driven Executive and Director with a proven track record over many years of successfully operating in multiple industries and markets. Shane was formerly CFO of an ASX Top 25 company (Mayne Nickless Limited (ASX: MAY)), as well as the inaugural CEO of Symbion Health (formerly known as Mayne Nickless Diagnostic Services). He also played a significant role in the float of Optus Communications. Over the past 20 years, Shane has been involved with multiple successful IPO’s (including Vitura in November 2019) and many large-scale mergers and acquisitions. He has served as either the Chair or Non-Executive Director on more than ten public company boards and many other private companies. He currently chairs an Australian company that is a global leader in the nuclear waste treatment industry, which includes working with the US Government in this space. Following the recent successful merger of both Paragon Care Limited (ASX: PGC) and pharmaceutical giant, CH2 (with combined annual sales of $3.3 billion), he now has freed up sufficient time and has now returned to the Board of Vitura and to assist the Company in re-establishing its leading presence in the Australian healthcare market.
Shane Tanner was appointed Non-Executive Director of Vitura on 27 November 2024, having previously served as the Company’s Independent Chair from 9 October 2018 to 11 April 2022. Shane is an experienced and driven Executive and Director with a proven track record over many years of successfully operating in multiple industries and markets. Shane was formerly CFO of an ASX Top 25 company (Mayne Nickless Limited (ASX: MAY)), as well as the inaugural CEO of Symbion Health (formerly known as Mayne Nickless Diagnostic Services). He also played a significant role in the float of Optus Communications. Over the past 20 years, Shane has been involved with multiple successful IPO’s (including Vitura in November 2019) and many large-scale mergers and acquisitions. He has served as either the Chair or Non-Executive Director on more than ten public company boards and many other private companies. He currently chairs an Australian company that is a global leader in the nuclear waste treatment industry, which includes working with the US Government in this space. Following the recent successful merger of both Paragon Care Limited (ASX: PGC) and pharmaceutical giant, CH2 (with combined annual sales of $3.3 billion), he now has freed up sufficient time and has now returned to the Board of Vitura and to assist the Company in re-establishing its leading presence in the Australian healthcare market.